elranatamab
pfizer
['magnetismm-3', 'multiplemyeloma', 'pfizer']
at #ash22, hear our oral presentation on results from the phase 2 magnetismm-3 study in triple-class exposed patients with relapsed/refractory #multiplemyeloma. read the abstract now.
Dedicated to communicating emerging science from Pfizer Oncology. Please see our community guidelines: https://t.co/MU3blmItSZ